STRYKER CORP
NYSE: SYK·Portage, Michigan·CIK 0000310764
- Price
- $310.72
- Base IV
- $185.16
Valuation snapshot
At $310.72, the price is above even our bull case of $279.51.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $185.16
- 60% of the price · range $100.00–$279.51
- Price vs base case
- 68% above
- $310.72 against $185.16
- Base case · our researched forecast, 2026-10-31See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $100.00 to bull $279.51. Values per share.
Price against each value
- Bear case
- $100.00
- Price 211% above
- No growth
- …
- —
- Base case
- $185.16
- Price 68% above
What does Stryker do?
Stryker provides medical devices, surgical instruments, and robotic-arm technology to hospitals and healthcare facilities to assist in orthopedic, neurosurgical, and vascular procedures.
It brought in $26.3B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Portage, Michigan
- Trades on
- NYSE as SYK
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 14¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 35¢ of every dollar.
- Making what it sells35¢
- Research and development6¢
- Sales, marketing and admin34¢
- Everything else it takes to operate4¢
- Interest and other costs1¢
- Tax6¢
- Left as profit14¢
Who pays Stryker, and for what?
Stryker sells medical technology, including surgical equipment, hospital products, minimally invasive devices and implants used in joint replacement and other surgeries. It earns revenue by selling these products and services through its own operations and distributors in about 61 countries.
Its customers are mainly doctors, hospitals and other healthcare facilities, which may buy directly or through third-party dealers and distributors.
MedSurg and Neurotechnology
62%Surgical equipment, endoscopy and communications systems, patient-care products, minimally invasive vascular devices and products for brain and skull-based procedures.
Stryker 1788 Platform for Minimally Invasive SurgeryImage: Stryker Orthopaedics
38%Implants and related technology used in joint replacement, trauma and extremities surgeries, including Mako robotic-arm assisted systems.
Stryker Mako SmartRobotics surgical system · March 2025Image: Stryker
Where its work physically happens, beyond headquarters:
- Stryker Cork Campus — Cork, Ireland. Stryker calls Cork its biggest innovation and manufacturing hub outside its U.S. headquarters, with more than 4,100 employees across six sites doing R&D and manufacturing, so a large share of global implant and device capacity sits here.
- Mahwah Orthopaedics Facility — Mahwah, United States. Mahwah is the hub for Stryker Orthopaedics, combining manufacturing, operations, distribution and commercial functions for hip and knee joint replacement, one of the company's largest franchises.
- Arroyo Manufacturing Plant — Arroyo, United States. Stryker describes Arroyo as one of the largest manufacturing facilities in its network, making Endoscopy and Instruments products, and Puerto Rico is named as a principal manufacturing location in the 10-K.
- Limerick Joint Replacement Plant — Limerick, Ireland. This 129,000 sq ft plant makes Stryker's knee and bone cement lines, which supply its joint replacement business.
- Salt Lake City Manufacturing Facility — Salt Lake City, United States. Stryker moved two manufacturing operations to this site, and an expansion announced in 2017 planned up to 540 jobs and about $100 million of investment; Utah is listed among the company's principal U.S. manufacturing locations.
How is the business doing?
Sales grew from $14.4B in 2020 to $25.1B in 2025, about 12% a year.
Running the business leaves about 21¢ of each sales dollar as operating profit, up from 15¢ in 2020.
After paying for its upkeep and new investment, it had $4.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Stryker says it works with customers to make healthcare better.
“Together with our customers, we are driven to make healthcare better.”
What management says it is working on now:
Grow sales
Stryker says its goal is sales growth at the high end of the medical technology industry.
Stryker 2025 Form 10-KInvest in acquisitions
The company says acquisitions are its first priority for allocating capital, to complement its portfolio of businesses.
Stryker 2025 Form 10-KDevelop and improve products
Stryker says future competitiveness depends largely on developing new products and improving existing ones.
Stryker 2025 Form 10-KExpand Mako robotics
Stryker continued expanding Mako's availability and applications, including a planned full U.S. launch of Mako Shoulder in early 2026.
Stryker 2025 Form 10-K
- Adjusted net earnings per diluted share, 2026
- $14.95 to $15.10
- Stryker Reports Second Quarter 2026 Operating Results
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is narrower than a year ago: 16¢ per sales dollar, against 19¢.
Since Oct 2026 the share price has risen 4%, from $297.60 to $310.72.
Recently
December 31, 2025
Annual Capital Expenditures as Share of Revenue changed to 3.0%
Stryker 2025 Form 10-KDecember 31, 2025
MedSurg and Neurotechnology Annual Net Sales changed to $15.6B
Stryker 2025 Form 10-K
Coming up
First quarter 2026
Mako Shoulder U.S. launch
Stryker planned a full U.S. commercial launch of its Mako Shoulder application, which combines shoulder implants, planning software and robotic assistance.
Stryker 2025 Form 10-KSecond half of 2026
Mako Shoulder on Mako 4
Stryker announced that Mako Shoulder would be available on its Mako 4 platform, expanding the platform's applications.
Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual MeetingMay 2026 through December 2028
EU medical-device transition deadlines
Stryker says it is on track to meet the European Union's extended medical-device regulation transition deadlines, which vary by device type.
Stryker 2025 Form 10-KFebruary 10, 2027
Senior notes repayment
Stryker has $500 million of senior unsecured notes scheduled to mature.
Stryker 2025 Form 10-K
Our own estimate moved too: the base case went from $152.83 to $185.16 a share between our last two valuations. The biggest reason: Annual Capital Expenditures as Share of Revenue moved from an unreported prior value to 3.0%, as reported in Stryker 2025 Form 10-K.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and product innovation
Stryker competes with global medical technology companies and says new products or procedures could make its offerings less attractive. If it cannot develop and launch products that customers adopt, sales could suffer.
From the company's own filingsWould hit how fast sales growStryker 2025 Form 10-K
Regulatory requirements
Medical devices face extensive and changing rules, including reviews before some products can be marketed. Delays, added costs or failure to comply could restrict sales or require recalls.
From the company's own filingsWould hit how fast sales growStryker 2025 Form 10-K
Supply interruptions and higher costs
Some materials, components and services come from single suppliers. Shortages, tariffs or higher prices could interrupt production, reduce sales or raise costs that Stryker may not be able to pass on to customers.
From the company's own filingsWould hit how much of each sale it keepsStryker 2025 Form 10-K
Pricing and healthcare budgets
Hospitals and other buyers face pressure to control costs, and governments and insurers can change prices or reimbursement. Lower payments or reduced coverage could affect demand and the prices customers will pay.
From the company's own filingsWould hit how fast sales growStryker 2025 Form 10-K
Acquisition integration
Stryker may not integrate acquired businesses as planned or achieve expected benefits. Integration can take management time and resources, and acquired businesses may not remain profitable.
From the company's own filingsWould hit how much of each sale it keepsStryker 2025 Form 10-K
Cybersecurity and technology disruptions
Stryker and its vendors rely on information systems, networks and connected products. A breach or outage could disrupt operations, expose information or lead to legal and regulatory costs.
From the company's own filingsWould hit how much of each sale it keepsStryker 2025 Form 10-K
First quarter 2026 revenue grew at a more modest 2.6% YoY, demonstrating potential quarterly volatility
From our researchWould hit how fast sales growStryker Q1 2026 Form 10-Q
Operating margin experienced seasonal dips to 15.5% in Q1 2026 and 15.9% in Q3 2026 due to commercial launch cadence
From our researchWould hit how much of each sale it keepsStryker Q3 2026 Financial Results
Is it a good business?
From 2016 to 2025 it earned between 8% and 14% on the capital invested in it, a median of 12%. Its cost of capital in the latest valuation is 8.1%; returns were above it in 9 of the 10 years.
From 2016 to 2025 it earned between 10% and 30% on its shareholders' equity, a median of 14%.
Over 10 years its operating margin ranged from 15¢ to 19¢ per sales dollar, a median of 18¢. Gross margin ran from 63¢ to 66¢.
Cost of capital 8.1%
The number of shares has held roughly steady over the past year.
It owes $11.7B more than it holds in cash, about 2.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $310.72. Our put its value between $100.00 and $279.51, with $185.16 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $100.00
This scenario envisions a cooling market where hospital budget squeezes and supply hurdles push annual sales growth well below recent double-digit levels while cost inflation trims overall business profitability.
Base case, $185.16
This scenario projects steady mid-single-digit sales gains in line with recent guidance as surgical procedure volumes normalize, accompanied by solid and stable bottom-line profitability across hospital equipment and implants.
Bull case, $279.51
This scenario anticipates a return to double-digit revenue expansion driven by rapid adoption of surgical robotics in outpatient clinics, translating into peak corporate profitability and robust cash flow.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 68%
For Stryker to be worth today's $310.72, sales would need to grow about 17.6% a year. We assume 6.5%. Over the last 5 years, sales grew 9.6% a year.
Or, if sales grow 6.5% as we assume, the price works with a profit margin of 32.4% (we assume 20.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 17.6% a year?
Try your own numbersWe're moderately sure of this range: it scores 65 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $185.16 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.5%
- Operating margin20.5%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$185.16 -40.4%


